Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.57 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 4/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14387783 | 0.84 | SIRT6 (0.57) | SIRT6JUNNFKB1NFKB2RELA | |
| SCHEMBL20398731 | 0.82 | SIRT6 (0.59) | SIRT6JUNNFKB1NFKB2RELA | |
| SCHEMBL26677090 | 0.80 | SIRT6 (0.57) | SIRT6JUNNFKB1NFKB2RELA | |
| SCHEMBL13539179 | 0.80 | SIRT6 (0.57) | SIRT6JUNNFKB1NFKB2RELA | |
| SCHEMBL15759622 | 0.78 | SIRT6 (0.53) | SIRT6GSK3BPTPN1 | |
| SCHEMBL12068884 | 0.78 | GSK3B (0.38) | SIRT6GSK3BPTPN1 | |
| SCHEMBL16600931 | 0.78 | PTPN1 (0.38) | SIRT6GSK3BPTPN1 | |
| SCHEMBL30263065 | 0.76 | SIRT6 (0.68) | SIRT6JUNNFKB1NFKB2RELA | |
| SCHEMBL27741418 | 0.76 | SIRT6 (0.68) | SIRT6JUNNFKB1NFKB2RELA | |
| SCHEMBL107129 | 0.76 | SIRT6 (0.68) | SIRT6JUNNFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420052-B2 | Imaging agents useful for identifying AD pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420052-B2 | Imaging agents useful for identifying AD pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420052-B2 | Imaging agents useful for identifying AD pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | APP, APBA1, PYGB | SIRT6 3997/4885JUN 4486/4885NFKB1 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.